Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Asset Writedowns and Impairment (2016)

Tenax Therapeutics' Asset Writedowns and Impairment history spans 5 years, with the latest figure at $33.3 million for Q4 2016.

  • For Q4 2016, Asset Writedowns and Impairment changed N/A year-over-year to $33.3 million; the TTM value through Dec 2016 reached $34.1 million, up 1975.38%, while the annual FY2016 figure was $33.3 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2016 was $33.3 million at Tenax Therapeutics, up from -$11563.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $33.3 million in Q4 2016 and bottomed at -$11563.0 in Q2 2014.
  • The 4-year median for Asset Writedowns and Impairment is $796954.5 (2012), against an average of $4.6 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 220.72% in 2012 against a maximum downside of 90.81% in 2012.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $802736.0 in 2012, then increased by 3.0% to $826846.0 in 2013, then plummeted by 101.4% to -$11563.0 in 2014, then surged by 287785.72% to $33.3 million in 2016.
  • Per Business Quant, the three most recent readings for TENX's Asset Writedowns and Impairment are $33.3 million (Q4 2016), -$11563.0 (Q2 2014), and $826846.0 (Q4 2013).